The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...

Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...

A new final guidance document published by the US Food and Drug Administration (FDA) recommends to sponsors methods of conducting clinical research in support of investigational medical device ...

University Hospitals Eye Institute in Cleveland has announced that it will begin offering patients the Argus II Retinal Prosthesis System, a “bionic eye” designed to treat late stage retinitis ...

This undated product image provided by Second Sight Medical Products shows a new implantable device that takes the place of damaged cells inside the eye. The Food and Drug Administration on Thursday, ...

USC and Second Sight Medical Products Inc., the developer of retinal prostheses for treating blindness, are expanding the clinical trial of an advanced retinal prosthesis into Europe. The announcement ...

Last year, Wentai Liu watched as surgeons implanted a microchip he had designed into the eye of a blind patient. For Liu, a professor of electrical engineering in the Baskin School of Engineering at ...

"Without the glasses you can't see a thing, put the glasses on you can suddenly see. You get that wow factor every time you do it." Philip Booth, 60, has had bionic eyes for the last three and a half ...

The Argus II, the latest device being studied in the clinical trial, is the second generation Retinal Prosthesis that consists of a 60–electrode grid that is surgically implanted on the retina. These ...

For more on June 24th's medical story, regarding the woman who lost her vision but is regaining her sight thanks to the system, visit http://www.2-sight.eu/en/product ...

Argus II Retinal Prosthesis fitted patients incurred a discounted incremental cost of 42,455 Euros in comparison to the patient given 'CAU' over the 25 years of time. Progressive improvement in the ...